Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?

One of the true biotech success stories, New York’s Regeneron has set its ambitions sky high with two blockbusters in their back pocket and some potential winners in the pipeline. But one of those bestsellers, immunology med Dupixent, hasn’t taken off quite as expected.